Provided herein are cytokine-immunoreceptor fusion proteins. Also provided herein are cells, polynucleotides, vectors, compositions, and methods directed to cytokine-immunoreceptor fusion proteins.

Provided herein are T-cell receptors (TCRs) that when expressed recombinantly on the surface of a T cell are able to recognize the DCAF4L2-derived peptide ILQDGQFLV (SEQ ID NO:1) when presented by HLA-A*02:01 sufficiently to activate the recombinant T cell. Importantly, exemplary TCRs provided herein were thoroughly screened for lack of cross-reactivity with similar peptides that may be presented by normal cells or tissue and for alloreactivity.

Provided are methods and compositions including for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.

The present disclosure relates generally to compositions and methods for modulating signal transduction mediated by interleukin-10 (IL10). In particular, the disclosure provides IL10 polypeptide variants with altered binding affinity to interleukin-10 receptor subunit beta (IL10Rb). Also provided are compositions and methods useful for producing such IL10 polypeptide variants, as well as methods for modulating IL10-mediated signaling, and/or for the treatment of conditions associated with the perturbation of signal transduction mediated by IL10.

The present invention provides a pluripotent stem cell expressing the following (a) and (b): (a) an exogenous gene encoding CC chemokine receptor 2 type B(CCR2B) (b) an exogenous gene encoding CC chemokine ligand 19 (CCL19), or an NK cell derived from the pluripotent stem cell or a progenitor cell thereof.

This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.

Provided are polynucleotides encoding inactivated cell surface receptors. Also provided are genetically engineered induced pluripotent stem cells (iPSCs) and derivative cells thereof expressing a chimeric antigen receptor (CAR) and methods of using the same. Also provided are compositions, polypeptides, vectors, and methods of manufacturing.

The present application relates to the technical field of chimeric antigen receptor T cell immunotherapy (CART), and in particular to a transgenic immune cell, and a construction method therefor and a use thereof. The present application provides a gene containing three coding regions, a recombinant nucleic acid containing the gene, a biological material, and a transgenic immune effector cell, wherein three functional proteins can be coded, and the expression of the three proteins enables an immune effector cell to have multiple functions, thereby reducing the inhibition effect of a solid tumor microenvironment on the immune effector cell, prolonging the time of the killing effect of the immune effector cell, and improving the anti-tumor efficacy of the immune effector cell.

Provided herein are constitutively active chimeric cytokine receptors (CACCRs). When present on chimeric antigen receptor (CAR)-bearing immune cells, such CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Also provided are methods of making and using the CACCRs described herein.